Revolutionizing Influenza Vaccines: New mRNA Universal Vaccine Clinical Trial Begins

2023-06-08 02:00:58

The flu was also the closest and most dangerous infectious disease until the Corona 19 epidemic. This daily routine of receiving influenza vaccine injections selected by predicting four types of epidemics before winter may change in the future. The US National Institute of Hygiene NIH announced that it had started a phase 1 clinical trial of a new mRNA vaccine that is effective against any type of influenza as a universal type.

In this clinical trial conducted by the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center and Duke University in North Carolina, healthy subjects between the ages of 18 and 49 were selected to inject an appropriate dose of the new vaccine. After that, follow-up observation is actually conducted for 1 year. It is said that it plans to figure out the effect by comparing it with people who have received the existing quadrivalent influenza vaccine.

A universal type influenza vaccine could be a significant advance in public health. It has the potential to relieve both the burden of developing a seasonal influenza vaccine every year and the burden on patients who need to receive annual injections. The NIAID side says that the current quadrivalent influenza vaccine has a problem that its effectiveness will drop significantly if the prediction of the epidemic type is wrong, but if it is a universal type, this worry will disappear. Moreover, it is said that it can prepare for dangerous mutant strains that have not yet appeared.

Of course, mRNA vaccine clinical trials have yet to begin, but a big change is about to come to influenza vaccines. Related information this placecan be found in

Related Articles:  Year of Change in Public Health: Top 5 Stories of 2023

1686190752
#Universal #type #flu #vaccine #begins #clinical #trials

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.